CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Sino Biopharmaceutical Limited - 1177 CFD

    2.86
    2.14%
    0.14
    Low: 2.76
    High: 2.88
    Market Trading Hours* (UTC) Opens on Monday at 01:30

    Mon - Fri: 01:30 - 04:00 05:00 - 08:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.14
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.024571 %
    Charges from full value of position ($-4.67)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.024571%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.002653 %
    Charges from full value of position ($0.50)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.002653%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency HKD
    Margin 5%
    Stock exchange Hong Kong
    Commission on trade 0%

    *Information provided by Capital.com

    Sino Biopharmaceutical Ltd ESG Risk Ratings

    High Medium Low Negligible

    ‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 2.8
    Open* 2.76
    1-Year Change* -24.59%
    Day's Range* 2.76 - 2.88
    52 wk Range 2.89-5.00
    Average Volume (10 days) 36.82M
    Average Volume (3 months) 940.71M
    Market Cap 54.90B
    P/E Ratio 28.10
    Shares Outstanding 18.80B
    Revenue 30.94B
    EPS 0.10
    Dividend (Yield %) 2.73973
    Beta 0.67
    Next Earnings Date Mar 29, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 22, 2023 2.86 0.10 3.62% 2.76 2.88 2.72
    Sep 21, 2023 2.80 -0.08 -2.78% 2.88 2.88 2.78
    Sep 20, 2023 2.88 0.00 0.00% 2.88 2.90 2.86
    Sep 19, 2023 2.88 -0.02 -0.69% 2.90 2.90 2.86
    Sep 18, 2023 2.88 0.00 0.00% 2.88 2.92 2.86
    Sep 15, 2023 2.90 0.04 1.40% 2.86 2.94 2.86
    Sep 14, 2023 2.86 0.00 0.00% 2.86 2.88 2.84
    Sep 13, 2023 2.86 -0.06 -2.05% 2.92 2.92 2.84
    Sep 12, 2023 2.90 0.00 0.00% 2.90 2.94 2.88
    Sep 11, 2023 2.94 0.08 2.80% 2.86 2.98 2.84
    Sep 7, 2023 2.88 -0.02 -0.69% 2.90 2.90 2.86
    Sep 6, 2023 2.90 0.00 0.00% 2.90 2.92 2.84
    Sep 5, 2023 2.92 -0.10 -3.31% 3.02 3.02 2.90
    Sep 4, 2023 3.02 0.10 3.42% 2.92 3.02 2.90
    Aug 31, 2023 2.92 -0.06 -2.01% 2.98 3.00 2.88
    Aug 30, 2023 2.98 -0.04 -1.32% 3.02 3.06 2.98
    Aug 29, 2023 3.02 0.06 2.03% 2.96 3.04 2.92
    Aug 28, 2023 2.92 -0.12 -3.95% 3.04 3.06 2.92
    Aug 25, 2023 2.94 0.00 0.00% 2.94 3.00 2.90
    Aug 24, 2023 2.94 0.04 1.38% 2.90 2.96 2.90

    Sino Biopharmaceutical Limited Events

    Time (UTC) Country Event
    Wednesday, October 4, 2023

    Time (UTC)

    12:00

    Country

    HK

    Event

    Sino Biopharmaceutical Ltd
    Sino Biopharmaceutical Ltd

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 28780.4 26861.4 23647.2 24234 20888.6
    Revenue 28780.4 26861.4 23647.2 24234 20888.6
    Cost of Revenue, Total 5795.51 5332.1 5182.32 4926.27 4196.93
    Gross Profit 22984.9 21529.3 18464.9 19307.8 16691.7
    Total Operating Expense 22409.8 21610.9 18307.6 18424.9 9366.15
    Selling/General/Admin. Expenses, Total 12564 12763.6 11628.6 11797 10268
    Interest Expense (Income) - Net Operating -172.512 -1110.37 -963.72 -561.3 -568.428
    Unusual Expense (Income) 25.527 639.276 -4.58 -0.903 -6557.24
    Other Operating Expenses, Total -55.912 308.971 -161.711 -134.863 -63.724
    Operating Income 6370.64 5250.5 5339.65 5809.16 11522.4
    Interest Income (Expense), Net Non-Operating -592.034 13322.2 -326.601 -118.565 -93.354
    Net Income Before Taxes 5778.6 18572.7 5013.04 5690.59 11429.1
    Net Income After Taxes 5002.62 16614.8 4340.67 4787.85 10732.8
    Minority Interest -2459.05 -2006.38 -1569.58 -2026.3 -1686.5
    Net Income Before Extra. Items 2543.57 14608.4 2771.09 2761.54 9046.35
    Net Income 2543.57 14608.4 2771.09 2761.54 9046.35
    Income Available to Common Excl. Extra. Items 2543.57 14608.4 2771.09 2761.54 9046.35
    Income Available to Common Incl. Extra. Items 2543.57 14608.4 2771.09 2761.54 9046.35
    Diluted Net Income 2311.2 14125.9 2771.09 2761.54 9046.35
    Diluted Weighted Average Shares 19017.2 19283 18800.3 18811.1 18548.5
    Diluted EPS Excluding Extraordinary Items 0.12153 0.73256 0.1474 0.1468 0.48771
    Dividends per Share - Common Stock Primary Issue 0.10598 0.06519 0.06172 0.04766 0.04292
    Diluted Normalized EPS 0.12269 0.76241 0.14719 0.14743 0.15597
    Research & Development 4253.15 3677.26 2626.71 2398.71 2090.57
    Dilution Adjustment -232.37 -482.511
    Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
    Total revenue 15277 13586.7 15193.7 26861.4 7110.79
    Revenue 15277 13586.7 15193.7 26861.4 7110.79
    Cost of Revenue, Total 3256.5 2835.91 2959.6 5332.1 1337.41
    Gross Profit 12020.5 10750.8 12234.1 21529.3 5773.38
    Total Operating Expense 11529.3 10636.8 11773 21610.9 5006.58
    Selling/General/Admin. Expenses, Total 6444.36 5630.1 6933.9 12703.6 3180.71
    Research & Development 2357.26 2204.55 2048.6 3677.26 767.055
    Interest Expense (Income) - Net Operating -137.247 17.194 -189.706 -818.075 -181.424
    Unusual Expense (Income) -14.761 -1.162 7.288 -3.731 -0.794
    Other Operating Expenses, Total -376.823 -49.832 13.321 719.681 -96.374
    Operating Income 3747.74 2949.91 3420.73 5250.5 2104.21
    Interest Income (Expense), Net Non-Operating -523.575 -925.918 333.884 13322.2 6032.95
    Net Income Before Taxes 3224.17 2023.99 3754.61 18572.7 8137.16
    Net Income After Taxes 2699.42 1819.4 3183.22 16614.8 7247.19
    Minority Interest -1440.64 -1196.86 -1262.18 -2006.38 -680.348
    Net Income Before Extra. Items 1258.78 622.533 1921.04 14608.4 6566.84
    Net Income 1258.78 622.533 1921.04 14608.4 6566.84
    Income Available to Common Excl. Extra. Items 1258.78 622.533 1921.04 14608.4 6566.84
    Income Available to Common Incl. Extra. Items 1258.78 622.533 1921.04 14608.4 6566.84
    Diluted Net Income 1258.78 551.1 1760.1 14125.9 6566.84
    Diluted Weighted Average Shares 18564.2 18911.7 19122.7 19283 19289.1
    Diluted EPS Excluding Extraordinary Items 0.06781 0.02914 0.09204 0.73256 0.34044
    Dividends per Share - Common Stock Primary Issue 0.01851 0.05299 0.05122 0.03259 0.01663
    Diluted Normalized EPS 0.06714 0.02909 0.09237 0.73258 0.34041
    Dilution Adjustment -71.433 -160.937 -482.511
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 25934.9 23503.2 22794.2 24913.1 18538.1
    Cash and Short Term Investments 16921.7 15794.1 16431.8 19105.6 13022.7
    Cash 6413.98 6213.97 6596.5 4340.18 3956.99
    Cash & Equivalents 2240.82 3385.56 4027.69 6291.03 2278.04
    Short Term Investments 8266.86 6194.51 5807.63 8474.34 6787.64
    Total Receivables, Net 6218.71 5537.26 4075.75 3342.97 3865.17
    Accounts Receivable - Trade, Net 4638.4 4220.67 2914.08 2712.21 2924.04
    Total Inventory 2328.84 1937.74 1880.05 1658.6 1209.16
    Prepaid Expenses 465.687 234.127 406.578 805.972 404.009
    Other Current Assets, Total 37.116
    Total Assets 64064.3 60543.3 47210.4 37514.2 49780.2
    Property/Plant/Equipment, Total - Net 9251.18 8516.06 8392.2 7633.22 5804.37
    Property/Plant/Equipment, Total - Gross 13858.3 12490.9 11475.9 10013.8 7176.27
    Accumulated Depreciation, Total -4607.08 -3974.82 -3083.65 -2380.6 -1371.91
    Goodwill, Net 662.611 647.93 88.926 88.926 13897
    Intangibles, Net 1251.84 1064.02 924.71 1324.21 8349.17
    Long Term Investments 25950.3 25875.1 11215.4 2582.92 1437.27
    Other Long Term Assets, Total 1013.41 937.04 3795.02 971.814 1754.29
    Total Current Liabilities 20150.7 15345 10943.5 8123.02 9668.62
    Accounts Payable 1637.35 1693.15 1947.8 1809.44 1832.17
    Accrued Expenses 6299.15 5145.84 4190.39 3560.56 3252.42
    Notes Payable/Short Term Debt 136.13 136.13 0 0 0
    Current Port. of LT Debt/Capital Leases 9723.84 6585.04 1581.52 689.828 2905.57
    Other Current Liabilities, Total 2354.2 1784.86 3223.82 2063.19 1678.46
    Total Liabilities 34317.2 30252.2 30463.3 22564.9 20567.4
    Total Long Term Debt 4258.12 5685.27 13067.5 7926.07 507.066
    Long Term Debt 3933.86 5365.32 12802.6 7884.8 507.066
    Deferred Income Tax 831.791 881.59 171.652 423.261 1522.06
    Minority Interest 8196.51 7437.91 5672.4 5611.94 8336.69
    Other Liabilities, Total 880.146 902.433 608.201 480.652 532.941
    Total Equity 29747 30291.1 16747.2 14949.2 29212.8
    Common Stock 414.899 415.44 415.895 278.451 278.846
    Additional Paid-In Capital 12461.4 12555.7 12668.7 12944.4 13020.5
    Retained Earnings (Accumulated Deficit) 19070.3 17926.7 4087.38 2435.23 16462.1
    Unrealized Gain (Loss) 93.701 533.078 400.958 37.067 287.199
    Other Equity, Total -860.86 -450.393 -355.848 -333.099 -378.576
    Total Liabilities & Shareholders’ Equity 64064.3 60543.3 47210.4 37514.2 49780.2
    Total Common Shares Outstanding 18468.1 18839.6 18861.5 18882.4 18910.1
    Treasury Stock - Common -1432.48 -689.347 -469.944 -412.837 -457.288
    Capital Lease Obligations 324.263 319.949 264.861 41.27
    Dec 2022 Jun 2022 Dec 2021 Jun 2021 Mar 2021
    Total Current Assets 25934.9 25197.8 23503.2 23813.3 21790.6
    Cash and Short Term Investments 16921.7 15674.8 15224.6 10443.3 10336.6
    Cash 6413.98 4212.46 6213.97 5576.28 5488.38
    Cash & Equivalents 2240.82 1852.99 3385.56 2452.05 1843.72
    Short Term Investments 8266.86 9609.39 5625.01 2415.02 3004.5
    Total Receivables, Net 5021.14 5354.76 4625.43 5174.74 3367.77
    Accounts Receivable - Trade, Net 4638.4 4947.84 4220.67 5059.33 3250.98
    Total Inventory 2328.84 2137.13 1937.74 1731.6 1813.05
    Prepaid Expenses 1663.26 2031.04 1715.45 6463.63 6273.18
    Total Assets 64064.3 64934.5 60543.3 56206.7 49152.8
    Property/Plant/Equipment, Total - Net 9251.18 8772.48 8516.06 8726.67 8762.28
    Goodwill, Net 662.611 642.552 647.93 906.031 890.829
    Intangibles, Net 1251.84 1214.07 1064.02 915.743 848.788
    Long Term Investments 25950.3 28168.1 25875.1 17467.1 12674.4
    Other Long Term Assets, Total 1013.41 939.52 937.04 4377.86 4185.88
    Total Current Liabilities 20150.7 16265.5 15345 11485.5 10358.5
    Accounts Payable 1637.35 2676.47 1693.15 1620.73 2161.74
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 9723.84 4118.2 6585.04 1845.84 1225.36
    Other Current Liabilities, Total 8789.49 9470.83 7066.83 8018.92 6971.36
    Total Liabilities 34317.2 34720.3 30252.2 31631.1 30487.2
    Total Long Term Debt 4258.12 7983.31 5685.27 12258.7 13038.2
    Long Term Debt 3933.86 7627.13 5365.32 11967.4 12774.5
    Capital Lease Obligations 324.263 356.177 319.949 291.359 263.713
    Deferred Income Tax 831.791 1025.56 881.59 773.501 326.033
    Minority Interest 8196.51 8530.46 7437.91 6533.45 6186.27
    Other Liabilities, Total 880.146 915.477 902.433 579.924 578.163
    Total Equity 29747 30214.2 30291.1 24575.6 18665.6
    Common Stock 414.899 414.942 415.44 415.895 415.895
    Retained Earnings (Accumulated Deficit) 19070.3 19267.9 17926.7 11801 18719.7
    Treasury Stock - Common -1432.48 -1378.6 -689.347 -469.944 -469.944
    Total Liabilities & Shareholders’ Equity 64064.3 64934.5 60543.3 56206.7 49152.8
    Total Common Shares Outstanding 18468.1 18815.2 18839.6 18861.5 18861.5
    Additional Paid-In Capital 12461.4 12465.8 12555.7 12668.7
    Unrealized Gain (Loss) 93.701 271.418 533.078 517.148
    Other Equity, Total -860.86 -827.306 -450.393 -357.207
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line 5778.6 18572.7 5013.04 5583.82 11429.1
    Cash From Operating Activities 6265.15 5366.29 5325.34 5324.63 5094.36
    Cash From Operating Activities 906.16 881.414 846.661 634.649 426.151
    Amortization 101.686 89.917 763.491 898.351 727.113
    Non-Cash Items 642.081 -12870.8 -512.005 -399.094 -6875.88
    Cash Taxes Paid 892.085 726.716 959.176 1102.09 838.547
    Cash Interest Paid 339.524 179.623 215.307 339.602 153.264
    Changes in Working Capital -1163.38 -1306.92 -785.855 -1393.09 -612.103
    Cash From Investing Activities -4070.82 -2515.98 -7845.56 -3824.34 -616.1
    Capital Expenditures -1402.68 -1741.06 -1495.16 -1481.14 -1565.7
    Other Investing Cash Flow Items, Total -2668.14 -774.915 -6350.4 -2343.2 949.599
    Cash From Financing Activities -3186.39 -3225.26 2233.19 2800.84 -2177.74
    Financing Cash Flow Items -2014.15 -452.366 -1724.7 -1512.43 -1167.66
    Total Cash Dividends Paid -1267.62 -938.489 -1187.02 -819.688 -710.328
    Issuance (Retirement) of Debt, Net 962.991 -1501.48 5340.28 5165.01 304.665
    Foreign Exchange Effects 47.322 -649.711 280.015 95.054 242.465
    Net Change in Cash -944.732 -1024.66 -7.016 4396.18 2542.99
    Issuance (Retirement) of Stock, Net -867.613 -332.93 -195.373 -32.05 -604.419
    Dec 2022 Jun 2022 Dec 2021 Jun 2021 Mar 2021
    Cash From Operating Activities 6265.15 3948.94 5366.29 2335.55
    Changes in Working Capital 6265.15 3948.94 5366.29 2335.55
    Cash From Investing Activities -4070.82 -5989.66 -2515.98 -4055.97
    Other Investing Cash Flow Items, Total -2827.49 -5362.69 -2515.98 -4055.97
    Cash From Financing Activities -3186.39 -1460.53 -3225.26 -761.689
    Financing Cash Flow Items -3367.9 -249.354 -3225.26 -761.689
    Foreign Exchange Effects 47.322 -32.85 -649.711 -113.766
    Net Change in Cash -944.732 -3534.09 -1024.66 -2595.87
    Capital Expenditures -1243.32 -626.972
    Issuance (Retirement) of Stock, Net -867.613 -809.316
    Issuance (Retirement) of Debt, Net 1049.12 -401.857
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Tse (Eric S Y) Individual Investor 21.5412 4050000000 0 2022-12-31
    France Investment China 1 Group Ltd Corporation 12.1229 2279254761 0 2023-06-30
    Tse (Ping) Individual Investor 8.8207 1658403124 27000000 2023-07-06 MED
    Cheng (Cheung Ling) Individual Investor 4.718 887034750 7000000 2023-04-04
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 1.7034 320264763 430000 2023-07-31 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 1.1206 210679106 -690000 2023-07-31 LOW
    First Sentier Investors (Hong Kong) Limited Investment Advisor 1.0121 190293500 -1957000 2023-04-30 LOW
    Tse (Hsin Stephen) Individual Investor 0.9268 174247000 0 2022-12-31
    State Street Global Advisors Asia Ltd. Investment Advisor/Hedge Fund 0.6738 126675943 5016808 2023-07-31 LOW
    Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.5832 109645878 -17217700 2022-12-31 LOW
    APG Asset Management N.V. Pension Fund 0.5599 105263158 -13607922 2023-03-31 LOW
    Bosera Asset Management Co., Ltd. Investment Advisor 0.4681 88013000 2208000 2022-12-31 LOW
    Goldman Sachs Asset Management, L.P. Investment Advisor 0.4668 87764104 1559585 2023-07-31 LOW
    Hang Seng Investment Management Ltd. Investment Advisor 0.4321 81233684 -2624015 2023-07-31 LOW
    Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.4245 79814490 2462000 2023-07-31 LOW
    California Public Employees' Retirement System Pension Fund 0.3818 71777747 -5538000 2022-06-30 LOW
    BlackRock Advisors (UK) Limited Investment Advisor/Hedge Fund 0.377 70878477 544000 2023-07-31 LOW
    Goldman Sachs Asset Management International Investment Advisor 0.3735 70221686 -1817000 2023-06-30 MED
    HSBC Global Asset Management (Hong Kong) Limited Investment Advisor 0.3517 66124984 0 2022-12-31 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.234 44002499 625000 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Sino Biopharmeceutical Company profile

    Sino Biopharmaceutical Limited, researches, develops, manufactures, and sells Chinese medicines and chemical medicines in Hong Kong, Mainland China, and internationally. The company operates in Modernized Chinese Medicines and Chemical Medicines, Investment, and Others segments. Its principal products include hepatitis medicines, such as Runzhong dispersible tablets, Tianqingganmei injections, Tianqingganping enteric capsules, Tianding tablets, Mingzheng capsules, and Ganlixin injections and capsules; and cardio-cerebral medicines comprising Kaishi injections, Yilunping and Tuotuo tablets, Tianqingning injections, and Beraprost Sodium tablets; and oncology medicines consisting of Zhiruo, Saiweijian, Tianqingyitai, and Qingweike injections, as well as Shoufu and Yinishu tablets, and Gelike capsules. The company's principal products also include Analgesic medicines, such as Kaifen injections and Zepusi Flurbiprofen Cataplasms; Orthopedic medicines, which comprise New Ossified Triol capsules and Jiuli tablets; anti-infectious medicines, including Tiance injections and Tianjie tablets; parenteral nutritious medicines, such as Xinhaineng and Fenghaineng fructose injections; respiratory system medicines, including Tianqingsule inhalation powder and Chia Tai Suke tablets; and anorectal medicines comprising Aisuping injections and Getai tablets. In addition, it develops medicines for liver, tumor, cardio-cerebral, analgesia, respiratory system, and orthopedic diseases; engages in the retail and distribution of pharmaceutical products; provides medical management consultancy services; and manufactures, sells, and distributes health food products, as well as is involved in optometry for optical glasses and sale of ophthalmic products. Further, the company provides research and development, medical technology development, and outpatient and surgical procedure services. The company was incorporated in 2000 and is headquartered in Wanchai, Hong Kong.
    Industry: Pharmaceuticals (NEC)

    湾仔港湾道1号会展广场辨公大楼41楼09室
    HK

    Income Statement

    • Annual
    • Quarterly

    News

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    Cable coils near lows ahead of Fed and BoE rate decisions

    It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

    14:16, 19 September 2023

    FTSE 100 Technical Outlook - 18 September 2023

    In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

    06:55, 19 September 2023
    View of the City of London’s illuminated financial district skyline at dusk

    Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

    The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

    13:46, 15 September 2023

    People also watch

    ETH/USD

    1,596.87 Price
    +0.150% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 5.40

    BTC/USD

    26,632.55 Price
    +0.180% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    XRP/USD

    0.52 Price
    -0.620% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    Oil - Crude

    90.14 Price
    +0.770% 1D Chg, %
    Long position overnight fee 0.0415%
    Short position overnight fee -0.0634%
    Overnight fee time 21:00 (UTC)
    Spread 0.030

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading